Innovacell

About Innovacell

Innovacell is a clinical-stage biotechnology company developing and commercializing autologous cell therapies for fecal and urinary incontinence. The company's core technology involves extracting a patient's own skeletal muscle cells, multiplying them in a specialized facility, and then reinjecting them into the weakened sphincter muscle to regenerate tissue and restore function. This approach aims to provide a permanent cure through a minimally invasive procedure.

The company's history began in 2000, when Innovacell Biotechnologie GmbH was founded in Innsbruck, Austria, as a spin-off from the Medical University of Innsbruck by Ekkehart Steinhuber and Rainer Marksteiner. The firm changed its corporate structure to an AG (a public limited company) in 2008 and focused on advancing its cell therapies through clinical trials. A significant restructuring occurred in 2021, when Innovacell K.K. was established in Tokyo, Japan, becoming the parent company to the Austrian entity (now Innovacell GmbH). This move was driven by Japan's favorable regulatory environment for regenerative medicine and its ambition to become a global leader in the field. The company went public on the Tokyo Stock Exchange in February 2026.

Innovacell's business model is described as a "Regenerative Medicine Product Global Aggregation Model," which involves identifying promising regenerative medicine candidates worldwide and leveraging its expertise to advance them through development and commercialization. The company's lead product candidate, ICEF15, is an autologous skeletal myoblast cell therapy for urge fecal incontinence, which is in multi-regional Phase III clinical trials in Europe and Japan. Other pipeline products include ICES13 for stress urinary incontinence (completed Phase II) and ICEF16 for passive fecal incontinence (preclinical). Innovacell has developed proprietary ultrasound-guided instruments for the precise injection of the cultivated cells. The company operates one of Europe's largest GMP-certified manufacturing facilities for cell cultivation in Innsbruck.